Phase 1 clinical trial
Researchers at the Yale Comprehensive Cancer Center developed and tested a novel cancer immunotherapy, MPDL3280A, based on a high-affinity antibody designed to bind to PD-L1-expressing cancer cells with a reduced cellular cytotoxicity profile. The potential treatment was administered to 277 patients with advanced incurable cancer and its impact was evaluated.
Multi-center Phase 2
clinical trial
POPLAR, a multi-center, randomized Phase 2 clinical trial, investigated the efficacy and safety of atezolizumab immunotherapy when compared with docetaxel, an alternative secondary treatment.
Randomized Phase 3 clinical trial
A randomized Phase 3 clinical trial (OAK) of the PD-L1 targeted therapy, atezolizumab, successfully demonstrated that atezolizumab treatment improved overall survival compared with docetaxel in 1,225 patients with advanced-stage NSCLC. Results confirm Phase 2 data from the POPLAR study, showing improved survival irrespective of PD-L1 expression status and histology, as well as increased durable responses with atezolizumab.
Read case study
Read case study
Read case study
POPLAR, a multi-center, randomized Phase 2 clinical trial, investigated the efficacy and safety of atezolizumab immunotherapy when compared with docetaxel, an alternative secondary treatment. PD-L1/PD-1 interactions can downregulate antitumor T cell functions, and blocking these interactions results in restoration of T cell activity. Prior studies have shown that direct targeting of PD-L1 with atezolizumab elicits durable antitumor responses. POPLAR is the first study on the effects of a PD-L1 checkpoint inhibitor in patients with previously treated non-small-cell lung cancer (NSCLC) and demonstrated significant improvement in overall survival with atezolizumab. Immune gene expression in pretreatment tumor specimens was analyzed in 287 patients using the Biomark platform. The T effector and IFNγ gene signatures were highly co-expressed in the tumor specimens, being associated with activated T cells, immune cytolytic activity and IFNγ expression. PD-L1, PD-1, PD-L2 and B7.1 gene expression was also assessed. Results showed improved overall survival with increasing PD-L1 expression with atezolizumab, whereas patients with the lowest PD-L1 expression when given atezolizumab experienced similar overall survival to those assigned to docetaxel. Thus, PD-L1 expression on tumor cells and tumor-infiltrating immune cells appears to be independently predictive of survival improvement with atezolizumab.
Researchers at the Yale Comprehensive Cancer Center developed and tested a novel cancer immunotherapy, MPDL3280A, based on a high-affinity antibody designed to bind to PD-L1-expressing cancer cells with a reduced cellular cytotoxicity profile. The potential treatment was administered to 277 patients with advanced incurable cancer and its impact was evaluated.
This Phase 1 clinical trial analyzed the mechanisms associated with clinical response to anti-PD-L1 therapy, aiming to evaluate the safety and tolerability of MPDL3280A and determine the maximum tolerated dose and any dose-limiting toxicities. Gene expression analysis was performed using TaqMan assays designed into an “immunochip” covering 94 genes on the Biomark platform for the presence of transcripts of immunological importance. Resulting data displayed expression patterns indicative of a generalized activation of CD8 and TH1 T cell responses.
A randomized Phase 3 clinical trial (OAK) of the PD-L1 targeted therapy, atezolizumab, successfully demonstrated that atezolizumab treatment improved overall survival compared with docetaxel in 1,225 patients with advanced-stage NSCLC. Results confirm Phase 2 data from the POPLAR study, showing improved survival irrespective of PD-L1 expression status and histology, as well as increased durable responses with atezolizumab.
The study aimed to investigate the efficacy and safety of atezolizumab compared with docetaxel in patients with locally advanced or metastatic, previously treated NSCLC. PD-L1 gene expression was assessed in tumor tissue using the Biomark gene expression platform. Expression analysis confirmed that patients with tumors expressing high levels of PD-L1 derived the greatest benefit from atezolizumab.
Exploring diagnostic and prognostic biomarkers for targeted therapy
Researchers from Hanover Medical School in Germany used circulating tumor cells and total RNA enriched from prostate cancer liquid biopsies to identify mRNA transcriptional signatures that correlated with known tissue-specific markers of tumor aggressiveness. Evaluation of relative transcript levels was enabled by high-throughput microfluidic qRT-PCR on the Biomark platform.
Read case study
Biomarker discovery and target validation
Researchers at the National Institute of Biology in Slovenia established and performed expression analysis using GlioBank, a centralized biobank of glioblastoma patient tissue samples, to facilitate the discovery of new biomarkers and treatment approaches that could improve patient outcomes. High-throughput qPCR with the Biomark platform enabled rapid and efficient profiling of 56 genes in over 100 samples.
Read case study
Researchers at the National Institute of Biology in Slovenia established and performed expression analysis using GlioBank, a centralized biobank of glioblastoma patient tissue samples, to facilitate the discovery of new biomarkers and treatment approaches that could improve patient outcomes. High-throughput qPCR with the Biomark platform enabled rapid and efficient profiling of 56 genes in over 100 samples – delivering high-quality, actionable data at scale. Real-time quantitative PCR was performed using the Biomark platform with 48.48 IFCs to determine the expression of genes associated with tumor subtype, overall patient survival and cancer cell invasiveness. This study demonstrates that gene expression analysis using Biomark systems with minimal sample input can uncover molecular signatures for patient stratification, prognosis, and drug target discovery and validation. Targeted analysis using the Biomark platform revealed gene expression signatures significantly associated with survival and identified an independent prognostic marker for poor overall survival in glioblastoma patients. Further comparative gene expression profiling between the tumor core and tumor rim regions identified distinct molecular signatures associated with glioblastoma invasiveness.
Dive deeper into this study
Researchers from Hanover Medical School in Germany used circulating tumor cells and total RNA enriched from liquid biopsies of men with oligometastatic prostate cancer relapse to identify mRNA transcriptional signatures that correlated with known tissue-specific markers of tumor aggressiveness. Evaluation of relative transcript levels of 54 gene targets in 44 patients was enabled by high-throughput qRT-PCR on the Biomark platform. This demonstrated the clinical value of quantifying blood-derived RNAs to identify patients who could benefit from intervention and supports expansion of novel diagnostic and prognostic biomarkers of treatment response. Transcript levels were significantly correlated with common tumor tissue assessments such as Gleason score and TNM classification. In the era of individualized treatment programs, validated biomarkers to guide intervention decisions are required. A high-throughput and automated Biomark platform and Delta Gene™ assays provided a cost-effective and time-saving approach for gene expression profiling, maximizing discovery potential from limited samples and leading to validated biomarkers predictive of treatment response.
Dive deeper into this study
Phase 1 clinical trial
Researchers at the Yale Comprehensive Cancer Center developed and tested a novel cancer immunotherapy, MPDL3280A, based on a high-affinity antibody designed to bind to PD-L1-expressing cancer cells with a reduced cellular cytotoxicity profile. The potential treatment was administered to 277 patients with advanced incurable cancer and its impact was evaluated.
Read case study
Exploring diagnostic and prognostic biomarkers for targeted therapy
Researchers from Hanover Medical School in Germany used circulating tumor cells and total RNA enriched from prostate cancer liquid biopsies to identify mRNA transcriptional signatures that correlated with known tissue-specific markers of tumor aggressiveness. Evaluation of relative transcript levels was enabled by high-throughput microfluidic qRT-PCR on the Biomark platform.
Read case study
Biomarker discovery and target validation
Researchers at the National Institute of Biology in Slovenia established and performed expression analysis using GlioBank, a centralized biobank of glioblastoma patient tissue samples, to facilitate the discovery of new biomarkers and treatment approaches that could improve patient outcomes. High-throughput qPCR with the Biomark platform enabled rapid and efficient profiling of 56 genes in over 100 samples.
Read case study
Multi-center Phase 2
clinical trial
POPLAR, a multi-center, randomized Phase 2 clinical trial, investigated the efficacy and safety of atezolizumab immunotherapy when compared with docetaxel, an alternative secondary treatment.
Read case study
Randomized Phase 3 clinical trial
A randomized Phase 3 clinical trial (OAK) of the PD-L1 targeted therapy, atezolizumab, successfully demonstrated that atezolizumab treatment improved overall survival compared with docetaxel in 1,225 patients with advanced-stage NSCLC. Results confirm Phase 2 data from the POPLAR study, showing improved survival irrespective of PD-L1 expression status and histology, as well as increased durable responses with atezolizumab.
Read case study
Phase 1 clinical trial
Researchers at the Yale Comprehensive Cancer Center developed and tested a novel cancer immunotherapy, MPDL3280A, based on a high-affinity antibody designed to bind to PD-L1-expressing cancer cells with a reduced cellular cytotoxicity profile. The potential treatment was administered to 277 patients with advanced incurable cancer and its impact was evaluated.
Read case study
Exploring diagnostic and prognostic biomarkers for targeted therapy
Researchers from Hanover Medical School in Germany used circulating tumor cells and total RNA enriched from prostate cancer liquid biopsies to identify mRNA transcriptional signatures that correlated with known tissue-specific markers of tumor aggressiveness. Evaluation of relative transcript levels was enabled by high-throughput microfluidic qRT-PCR on the Biomark platform.
Read case study
Biomarker discovery and target validation
Researchers at the National Institute of Biology in Slovenia established and performed expression analysis using GlioBank, a centralized biobank of glioblastoma patient tissue samples, to facilitate the discovery of new biomarkers and treatment approaches that could improve patient outcomes. High-throughput qPCR with the Biomark platform enabled rapid and efficient profiling of 56 genes in over 100 samples.
Read case study
Multi-center Phase 2
clinical trial
POPLAR, a multi-center, randomized Phase 2 clinical trial, investigated the efficacy and safety of atezolizumab immunotherapy when compared with docetaxel, an alternative secondary treatment.
Read case study
Randomized Phase 3 clinical trial
A randomized Phase 3 clinical trial (OAK) of the PD-L1 targeted therapy, atezolizumab, successfully demonstrated that atezolizumab treatment improved overall survival compared with docetaxel in 1,225 patients with advanced-stage NSCLC. Results confirm Phase 2 data from the POPLAR study, showing improved survival irrespective of PD-L1 expression status and histology, as well as increased durable responses with atezolizumab.
Read case study
Phase 1 clinical trial
Researchers at the Yale Comprehensive Cancer Center developed and tested a novel cancer immunotherapy, MPDL3280A, based on a high-affinity antibody designed to bind to PD-L1-expressing cancer cells with a reduced cellular cytotoxicity profile. The potential treatment was administered to 277 patients with advanced incurable cancer and its impact was evaluated.
Read case study
Exploring diagnostic and prognostic biomarkers for targeted therapy
Researchers from Hanover Medical School in Germany used circulating tumor cells and total RNA enriched from prostate cancer liquid biopsies to identify mRNA transcriptional signatures that correlated with known tissue-specific markers of tumor aggressiveness. Evaluation of relative transcript levels was enabled by high-throughput microfluidic qRT-PCR on the Biomark platform.
Read case study
Biomarker discovery and target validation
Researchers at the National Institute of Biology in Slovenia established and performed expression analysis using GlioBank, a centralized biobank of glioblastoma patient tissue samples, to facilitate the discovery of new biomarkers and treatment approaches that could improve patient outcomes. High-throughput qPCR with the Biomark platform enabled rapid and efficient profiling of 56 genes in over 100 samples.
Read case study
Multi-center Phase 2
clinical trial
POPLAR, a multi-center, randomized Phase 2 clinical trial, investigated the efficacy and safety of atezolizumab immunotherapy when compared with docetaxel, an alternative secondary treatment.
Read case study
Randomized Phase 3 clinical trial
A randomized Phase 3 clinical trial (OAK) of the PD-L1 targeted therapy, atezolizumab, successfully demonstrated that atezolizumab treatment improved overall survival compared with docetaxel in 1,225 patients with advanced-stage NSCLC. Results confirm Phase 2 data from the POPLAR study, showing improved survival irrespective of PD-L1 expression status and histology, as well as increased durable responses with atezolizumab.
Read case study
Phase 1 clinical trial
Researchers at the Yale Comprehensive Cancer Center developed and tested a novel cancer immunotherapy, MPDL3280A, based on a high-affinity antibody designed to bind to PD-L1-expressing cancer cells with a reduced cellular cytotoxicity profile. The potential treatment was administered to 277 patients with advanced incurable cancer and its impact was evaluated.
Read case study
Exploring diagnostic and prognostic biomarkers for targeted therapy
Researchers from Hanover Medical School in Germany used circulating tumor cells and total RNA enriched from prostate cancer liquid biopsies to identify mRNA transcriptional signatures that correlated with known tissue-specific markers of tumor aggressiveness. Evaluation of relative transcript levels was enabled by high-throughput microfluidic qRT-PCR on the Biomark platform.
Read case study
Biomarker discovery and target validation
Researchers at the National Institute of Biology in Slovenia established and performed expression analysis using GlioBank, a centralized biobank of glioblastoma patient tissue samples, to facilitate the discovery of new biomarkers and treatment approaches that could improve patient outcomes. High-throughput qPCR with the Biomark platform enabled rapid and efficient profiling of 56 genes in over 100 samples.
Read case study
Multi-center Phase 2
clinical trial
POPLAR, a multi-center, randomized Phase 2 clinical trial, investigated the efficacy and safety of atezolizumab immunotherapy when compared with docetaxel, an alternative secondary treatment.
Read case study
Randomized Phase 3 clinical trial
A randomized Phase 3 clinical trial (OAK) of the PD-L1 targeted therapy, atezolizumab, successfully demonstrated that atezolizumab treatment improved overall survival compared with docetaxel in 1,225 patients with advanced-stage NSCLC. Results confirm Phase 2 data from the POPLAR study, showing improved survival irrespective of PD-L1 expression status and histology, as well as increased durable responses with atezolizumab.
Read case study